-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, Gilead's TROP-2 ADC Trodelvy, In Combination With Keytruda, Shows Clinically Meaningful Survival Gains And Fewer Adverse Event-Related Discontinuations In ASCENT-04

Benzinga·06/02/2025 07:53:11
Listen to the news
  • First Pivotal Phase 3 Trial to Show Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care in 1L Metastatic TNBC –
  • Early Trend in Improvement in Overall Survival Observed